Table 1.
Subject characteristics
| Normal | Mild | Mild/mod+ICS | Severe | p Value | |
|---|---|---|---|---|---|
| Age (±SD) | 34±12 | 33±15 | 33±11 | 43±12 | 0.004 |
| Race*, n (%) | 22/2/3 (81/7/11) | 8/0/1 (89/0/11) | 12/4/4 (60/20/20) | 34/7/3 (77/16/7) | 0.42 |
| Sex (M/F), n (%) | 14/13 (52/48) | 2/7 (22/78) | 6/14 (30/70) | 11/33 (25/75) | 0.10 |
| FEV1% pred (±SD) | 100±2 | 91±3 | 90±4 | 56±3 | <0.0001 |
| FEV1 reversal % (±SEM) | 6±0.8 | 9±3 | 11±2 | 33±5 | <0.0001 |
| Eosinophils in sputum, % (25th–75th percentiles) | 0.9 (0–3.6) | 5 (0.3–8.3) | 1 (0.4–2.8) | 6.9 (1.8–31.3) | 0.0012 |
| Age at onset, median (25th–75th percentiles) | NA | 12 (5–40) | 5 (2–14) | 8 (2–32) | 0.26 |
| Atopy (Y/N) | 14/13 | 9/0 | 16/2 | 29/8 | 0.002 |
*
Caucasian/African American/other.
FEV1% pred, forced expiratory volume in 1 s % predicted; ICS, inhaled corticosteroid; NA, not applicable.